



(51) International Patent Classification:

C07D 213/81 (2006.01) **C07D 413/04** (2006.01)
C07D 241/28 (2006.01) **C07D 413/12** (2006.01)
C07D 401/04 (2006.01) **A61K 31/443** (2006.01)
C07D 403/04 (2006.01) **A61P 11/12** (2006.01)
C07D 405/12 (2006.01)

(21) International Application Number:

PCT/EP2011/054038

(22) International Filing Date:

17 March 2011 (17.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/315,509 19 March 2010 (19.03.2010) US
61/441,853 11 February 2011 (11.02.2011) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAETTIG, Urs** [CH/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **BALA, Kamlesh Jagdis** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **BUDD, Emma** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **EDWARDS, Lee** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **HOWSHAM, Catherine** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **HUGHES, Glyn** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre,

Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **LEGRAND, Darren Mark** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **SPIEGEL, Katrin** [CH/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB).

(74) Agent: **MUELLER, Philippe**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF

(57) Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sicca, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

